Q2 2026 saw 12.7% revenue growth to $740.3 million, but a $144.2 million goodwill impairment led to a net loss from continuing operations. Adjusted EBITDA declined to $132.0 million, and a restructuring plan was launched to drive future savings. The pending Diabetes Health business sale and recent…
Q2 2026 saw 12.7% revenue growth to $740.3 million, but a $144.2 million goodwill impairment led to a net loss from continuing operations. Adjusted EBITDA declined to $132.0 million, and a restructuring plan was launched to drive future savings. The pending Diabetes Health business sale and recent refinancing are expected to strengthen the balance sheet.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
